Andy Studna, Editor

NBI-1070770 is a novel, selective, and orally active, negative allosteric modulator.

Multiple sites will be added to the trial through collaboration with network of community-based oncology practices.

A study conducted by the Tufts CSDD in collaboration with CluePoints and PwC revealed that slightly more than half of sponsors and contract research organizations have adopted risk-based quality management approaches.

In part 2 of this video interview with ACT editor Andy Studna, Tirisham Gyang, MD, assistant professor of neurology at The Ohio State University discusses how industry can effectively enroll patients from underrepresented populations into their trials.

Open label, dose-escalation trial is testing the efficacy of LyGenesis’ first-in-class allogenic regenerative cell therapy.

In part 1 of this video interview with ACT editor Andy Studna, Tirisham Gyang, MD, assistant professor of neurology at The Ohio State University discusses how new research is changing the way industry recognizes multiple sclerosis in non-white populations.

Systematic review of available literature aimed to identify the most prominent barriers affecting enrollment in oncology drug trials.

While there is still potential left to be unlocked, current uses of artificial intelligence in clinical research include drug discovery, determining patient disposition, and dosing.

Over a 3.5-year period, members of EU-PEARL developed revamped templates for integrated research platforms to address their evolving complexity.

In the fourth and final part of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the key features of O2P as well as plans for further development of the hydrocodone prodrug.

In part 3 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the development journey of his company's hydrocodone prodrug, O2P.

Systematic review of over 800 retracted articles suggest that better identification of postretraction citations should be implemented.

In part 2 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses what industry should be keeping top of mind when it comes to designing and executing pain clinical studies.

In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.

Combination demonstrated a favorable trend toward overall survival in non-small cell lung cancer patients.

Systematic review of 127 recent platform trials showed insufficient reporting of important trial information.

Despite improvements, results from the study of SLS-005 (IV trehalose), a low molecular weight disaccharide, did not meet statistical significance.

Results of cross-sectional study of 50 discharge summaries suggest a large language model can be used to increase their understandability.

Analysis of trial results show Imfinzi and Lynparza displayed a strong clinical benefit and more than doubled median duration of response vs. chemotherapy.

Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients based on results from the pivotal Phase III KarMMa-3 study.

Cross-sectional study of recent FDA drug approvals evaluated how closely they were aligned with US and global burden of disease.

Collaboration brings Flatiron’s oncology-specific decision support platform to oncology care clinicians at MUSC Hollings Cancer Center.

Effective immediately, the acquisition strengthens both organizations’ abilities to recruit and retain diverse populations for clinical trials.

Tola Olorunnisola, senior vice president – general manager, clinical services and strategy, at Avantor, discusses the progress and challenges in incorporating more diversity-driven measures in drug development.

Investigational, once-weekly combination shows promise as long-acting oral treatment option for those virologically suppressed with HIV.

Gilead’s Veklury (remdesivir), a nucleotide analog prodrug, was associated with lower risk of developing long-COVID.

Gadi Saarony, CEO of Advarra discusses the current state of diversity in clinical trials and how industry needs to be more proactive in addressing it.

Elysium Therapeutics’ proprietary O2P is a hydrocodone prodrug for the treatment of moderate-to-severe acute pain.

While little research on open-cohort designs currently exists, could this design be a solution to challenges currently seen in closed-cohort designs?

DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR).